Genetic Testing for Antidepressants: What It Can and Can't Tell You
Author:
Blossom Editorial
Finding an antidepressant that works for you can take more than one try, and that trial-and-error process can stretch over months. Genetic testing for antidepressants, also called pharmacogenomic or PGx testing, promises to shorten that search by analyzing how your body processes certain medications.
Understanding what these tests measure, what the evidence actually supports, and where their limits lie can help you have a more informed conversation with your prescriber and determine if this can be an option for you.
Key Takeaways
Trial and error is still the norm: Many people need to try more than one antidepressant before finding one that helps, and each trial usually takes several weeks to evaluate, which is a large part of why interest in genetic testing has grown.
The tests measure metabolism, not mood: The most useful information on antidepressants comes from genes involved in drug metabolism, particularly CYP2D6, CYP2C19, and CYP2B6, which affect how quickly your body breaks down certain medications. They describe how you process a drug, not whether that drug will improve your mood. Although some commercial panels also test genes related to drug targets or serotonin signaling, current evidence does not support using all of these genes to guide antidepressant prescribing.
Treat results as one input, not a verdict: Before paying for a test, it's reasonable to ask your prescriber how the results would actually change your treatment plan.
What is Genetic Testing for Antidepressants?
Genetic testing for antidepressants is a form of pharmacogenomic testing, sometimes shortened to PGx. Pharmacogenomics is described as the study of how genes affect a person's response to drugs, with the goal of providing individualized treatment that benefits them while preventing serious side effects.
In psychiatry, most of these tests focus on genes that code for liver enzymes in the cytochrome P450 family. Two come up most often:
CYP2C19: Involved in processing several selective serotonin reuptake inhibitors (SSRIs), including citalopram (Celexa), escitalopram (Lexapro), and sertraline (Zoloft).
CYP2D6: Involved in processing medications such as paroxetine (Paxil), fluvoxamine (Luvox), venlafaxine (Effexor), and vortioxetine (Trintellix), as well as several tricyclic antidepressants, including amitriptyline and nortriptyline.
The U.S. FDA lists gene-drug pairs for which it considers the scientific evidence sufficient to indicate that genetic differences may affect drug metabolism and, in some cases, treatment effects or adverse-event risk. Several antidepressants appear on that list. However, inclusion in the table does not necessarily mean the FDA recommends testing before prescribing.
Depending on your variants, a lab may describe you as a poor, intermediate, normal, rapid, or ultrarapid metabolizer for a given enzyme. A poor metabolizer clears a medication slowly, which can mean higher levels at a standard dose, while an ultrarapid metabolizer clears it quickly. That helps explain why two people on the same dose can have very different experiences.
It must be highlighted that genotype is not the only factor affecting drug metabolism. Other factors, including drug interactions, age, liver function, and other health characteristics, can also change how a drug is processed.
How Does the Test Work?
The process itself is simple, which is part of the appeal. Most pharmacogenomic panels used in mental health follow the same basic steps:
Sample collection: Usually a cheek swab, sometimes a blood draw, collected in a clinic or through an at-home kit ordered by your prescriber.
Lab analysis: The lab looks for specific variants in a defined set of genes. Panels differ in how many genes they include.
A report for your prescriber: Results may place medications into categories or provide dosing or caution recommendations, but the categories and algorithms vary between laboratories. A result should therefore be interpreted according to the specific test's methodology and established gene-drug guidelines.
A conversation about next steps: Your prescriber reads the report alongside your symptoms, history, and what you've already tried.
Turnaround is usually a matter of days to a couple of weeks, and varies by laboratory and type of test.
What Does the Research Say?
Marketing for these tests can suggest they will find the right antidepressant for you. The research says something more modest. It helps to know the starting point. The National Institute of Mental Health (NIMH) notes that antidepressants take four to eight weeks to work, and that it often takes more than one try to find the right fit.
Testing does change what doctors prescribe. In the PRIME Care trial, 45% of patients in the pharmacogenomic-guided group were prescribed an antidepressant with no predicted drug-gene interaction, compared with 18% receiving usual care.
In the same trial, pharmacogenomic-guided care was associated with a small overall increase in remission during the 24-week study, but the difference was not statistically significant at week 24. The main consistent benefit was a reduction in prescriptions with predicted gene-drug interactions.
In the GUIDED trial, the primary measure of overall symptom improvement was not significantly different between groups: 27.2% under guided care vs. 24.4% under usual treatment. However, more people achieved the study's definitions of response and remission with pharmacogenomic-guided care than with usual care.
More recent meta-analyses continue to find small short-term improvements in response or remission with some pharmacogenomic-guided approaches, but results vary considerably by study and test platform. Benefits are generally less clear at longer follow-up, and some analyses have raised concerns about study quality and publication bias.
Regulators have stayed cautious. The FDA's table of gene-drug pairs notes that listing a pair does not mean the agency recommends testing before prescribing. When it authorized the first direct-to-consumer test in 2018, it required a warning with the results: the test does not tell you whether a medication is right for you, and you should not use it to stop or change one.
In practice, prescribers still weigh your symptoms, your side effects, your other medications, and what has worked for blood relatives. Mayo Clinic's guidance lists those factors, not genetics, as the main ones. A test can add context to that picture. If your current medication isn't helping, a conversation about switching antidepressants may matter more than any test result.
What Genetic Testing Can't Tell You
Knowing the limits matters as much as knowing what a test measures. When the FDA authorized the first direct-to-consumer pharmacogenetic reports, it stated plainly that such tests do not determine whether a medication is appropriate and do not diagnose any condition. Pharmacogenomic panels generally cannot:
Diagnose depression or any other condition: Diagnosis comes from a clinical evaluation.
Predict with certainty whether a medication will relieve your symptoms: Genotype is only one factor that can affect drug metabolism, and metabolism, in turn, is only one of several factors that dictate how well a drug works.
Account for everything else that shapes your response: Other medications, alcohol, sleep, stress, and how consistently you take a medication all influence outcomes.
Replace the usual trial period: PGx results do not tell you in advance exactly how you will respond. Your prescriber still needs to monitor symptoms, side effects, and response over time and decide whether to continue, adjust, or change treatment.
Determine your dose on its own: PGx can help inform dosing for certain antidepressants with established gene-drug recommendations, but it does not determine the right dose by itself. Your prescriber must also consider your symptoms, response, side effects, other medications, and health history.
It's also worth noting that panels vary. Two labs may test different genes, use different cutoffs, and present results with different color-coded categories, so a result from one company is not always directly comparable to another.
Who Might Consider Testing?
Routine pharmacogenomic testing before a first antidepressant trial is not currently recommended by several major guidelines. It tends to come up in more specific situations:
Poor response to one or more adequate trials: If an antidepressant has not worked despite an adequate trial, or if you've had repeated unusual side effects, your prescriber may consider pharmacogenomic testing alongside other ways of assessing why treatment hasn't worked.
Side effects appear quickly or at low doses: Unusual sensitivity can sometimes fit with slower metabolism of a particular drug.
Little or no response despite an adequate dose and trial: Rapid metabolism is one possible explanation among several, but poor response can have many causes. PGx results may provide additional context when an actionable gene-drug interaction is relevant.
You take several medications that interact through the same enzymes: PGx results can provide useful information when several medications depend on the same metabolic pathway, but your current medication list still matters because some drugs can inhibit or induce these enzymes and change your actual drug metabolism.
Even in these cases, a test is one input. A careful review of what you've taken, at what dose, for how long, and with what side effects usually carries more weight.
Cost and Insurance Coverage
What you pay varies widely depending on the lab, the panel, and your plan. Some labs bill insurance directly and advertise a capped out-of-pocket amount, while others charge cash prices running into the hundreds of dollars.
Coverage varies by insurer, plan, test, and clinical situation. Some policies cover PGx testing only when there is a specific actionable gene-drug interaction and defined medical-necessity criteria; broader panels may be deemed investigational and not be covered. Because the rules differ so much by plan, a few questions tend to save money and frustration:
Is this specific lab and panel covered under my plan, and is prior authorization required?
What will I owe if the test isn't covered, and is there a laboratory-specific cash price or financial-assistance program?
Will the results change what my prescriber does next?
It's also worth understanding your broader mental health benefits, since visits and medications are usually the larger ongoing expense. Our guide on insurance coverage for depression treatment walks through what plans commonly cover.
When to Talk to a Healthcare Provider
Genetic testing is a question for a prescriber, not something to act on alone. It's worth starting that conversation if:
You've tried two or more antidepressants without meaningful improvement
You consistently get side effects at doses most people tolerate well
You're taking several medications and want to understand possible interactions
You've already had pharmacogenomic testing, perhaps through another provider or a direct-to-consumer service, and want help interpreting it
You're considering stopping a medication because of cost, side effects, or frustration with the process
One thing worth saying plainly: don't stop or change an antidepressant on your own based on a test result. Stopping abruptly can cause discontinuation symptoms, and a report suggesting slower metabolism doesn't automatically mean a medication is wrong for you.
How Blossom Health Can Help
Blossom Health connects you with board-certified psychiatric providers for virtual, in-network visits. Our providers help evaluate symptoms, make a diagnosis, and develop individualized treatment plans for a range of mental health conditions. They can discuss genetic testing for antidepressants and whether that’s recommended for you.
The platform works with several insurance plans. You can get started with Blossom Health by checking your coverage here.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. If you are experiencing a mental health crisis, call or text the 988 Suicide and Crisis Lifeline.
Sources
U.S. Food and Drug Administration. (September 10, 2026). Table of Pharmacogenetic Associations. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations
U.S. Food and Drug Administration. (October 31, 2018). FDA authorizes first direct-to-consumer test for detecting genetic variants that may be associated with medication metabolism. https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-direct-consumer-test-detecting-genetic-variants-may-be-associated-medication
Oslin, D. W., Lynch, K. G., Shih, M.-C., et al. (2022). Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: The PRIME Care randomized clinical trial. JAMA, 328(2), 151–161. https://jamanetwork.com/journals/jama/fullarticle/2794053
Greden, J. F., Parikh, S. V., Rothschild, A. J., et al. (2019). Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of psychiatric research, 111, 59–67. https://pubmed.ncbi.nlm.nih.gov/30677646/
Brown LC, Stanton JD, Bharthi K, Al Maruf A, Müller DJ, Bousman CA. (2022). Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials. PMID 36111494, doi:10.1002/cpt.2748. https://pubmed.ncbi.nlm.nih.gov/36111494/
MedlinePlus Genetics, U.S. National Library of Medicine. (March 22, 2022). What is pharmacogenomics? https://medlineplus.gov/genetics/understanding/genomicresearch/pharmacogenomics/
National Institute of Mental Health. (December 2023). Mental Health Medications. https://www.nimh.nih.gov/health/topics/mental-health-medications
National Human Genome Research Institute. (September 22, 2026). Pharmacogenomics, Genetics Glossary. https://www.genome.gov/genetics-glossary/Pharmacogenomics
National Human Genome Research Institute. (January 13, 2020). Frequently Asked Questions About Pharmacogenomics. https://www.genome.gov/FAQ/Pharmacogenomics
Mayo Clinic. (September 23, 2022). Antidepressants: Selecting one that's right for you. https://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046273
